Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)
Launched by ORGANON AND CO · Oct 26, 2006
Trial Information
Current as of June 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Low back pain for previous 3 months and majority of days in last month
- • Regular use of acetaminophen or NSAID to treat low back pain in past month
- • Judged to be in otherwise good health
- Exclusion Criteria:
- • Low back pain that is due to secondary causes
- • Radicular/myelopathic pain
- • Surgery for low back pain within the past 6 months
- • Active lawsuit or claim pertaining to their low back pain
- • Disease that may confound the results of the study or pose risk to the patients
- • Corticosteroid use in past month
- • Previous participation in MK0663 study
About Organon And Co
Organon & Co. is a global healthcare company dedicated to advancing women's health and improving patient outcomes through innovative therapies and solutions. With a strong focus on addressing unmet medical needs, Organon develops and commercializes a diverse portfolio of medicines, including reproductive health, contraception, and other critical areas affecting women's health. Committed to scientific excellence and collaboration, the company engages in clinical trials to explore new treatment avenues and enhance the quality of life for patients worldwide. Through its mission-driven approach, Organon strives to empower women and healthcare providers with the tools and resources necessary for informed decision-making and effective care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Medical Monitor
Study Director
Merck Sharp & Dohme LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials